📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-18 17:59
161 analysed today
FollowTelegram
161
Today
149,562
All-time analysed
42,894
Positive
6,654
Negative
91,341
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
28 announcements match the current filters (relevance ≥ 5).
Q1 PAT Down 5% YoY to ₹38.6 Cr; Approves ₹69.7 Cr Buyback at up to ₹500/Share
Advanced Enzyme Technologies reported Q1 FY27 consolidated revenue of ₹189.8 Cr (+2% YoY, -7% QoQ) and PAT of ₹38.6 Cr (-5% YoY, -15% QoQ), impacted by a timing-related sales reversal of ₹10 Cr. EBITDA margins contracted to 27% (down from 30% in Q1 FY26) due to higher power and fuel costs and product mix shifts. Growth was driven by Specialized Manufacturing (+41% YoY) and Bioprocessing (+30% YoY), while Human Healthcare fell 7% YoY. The Board also approved an open-market buyback of up to ₹69.7 Cr at a ceiling price of ₹500 per share and the acquisition of the remaining 4.28% stake in JC Biotech for ₹7.98 Cr.
Confidence: HIGH
What changedRelease of Q1 FY27 earnings call transcript highlighting segment trends, a ₹10 Cr sales reversal, and the approval of a ₹69.7 Cr share buyback.
Why it mattersClarifies operating margin headwinds from elevated energy costs and provides visibility on capital allocation via subsidiary full ownership and share repurchases.
Q1 FY27 Revenue: ₹189.8 CrQ1 FY27 EBITDA Margin: 27%Q1 FY27 PAT: ₹38.6 CrBuyback Maximum Value: ₹69.7 CrBuyback as % of Market Cap: ~1.97%JC Biotech Stake Acquisition Value: ₹7.98 Cr
📅 Short termMuted quarterly performance may weigh on sentiment, though the ₹500/share ceiling price for the buyback offers near-term valuation support.
📈 Long termStrong traction in high-margin Specialized Manufacturing and complete integration of JC Biotech support long-term compounding toward target 15% revenue growth.
⚠ Risk flags
- Margin volatility from elevated energy and power costs
- Demand slowdown in the Pharma API/Human Healthcare segment
- Extended working capital cycle of 125-138 days
Key Highlights
Q1 FY27 consolidated revenue rose 2% YoY to ₹189.8 Cr, impacted by a ₹10 Cr revenue reversal.
EBITDA dropped 10% YoY to ₹51.0 Cr with EBITDA margin declining to 27% vs 30% YoY.
Board approved a share buyback of up to ₹69.7 Cr at a maximum price of ₹500 per share via open market.
Acquired remaining 4.28% stake in JC Biotech for ₹7.98 Cr, making it a 100% wholly-owned subsidiary.
👀 What to Watch
Track recovery in the core Human Healthcare/Pharma API segment in Q2 FY27 and monitor the execution and progress of the open-market buyback program.
₹69.7 Cr Buyback Approved at ₹500/Share via Open Market Route
Advanced Enzyme Technologies has approved a share buyback of up to ₹69.7 crore through the open market route. The maximum buyback price is set at ₹500 per share, representing a significant premium of approximately 66.7% over the current market price of ₹299.9. The company is mandated to utilize at least 75% of the buyback size (₹52.275 crore). This buyback represents 9.99% of the company's standalone paid-up capital and free reserves as of March 31, 2026.
Confidence: HIGH
What changedThe company has formally approved and certified the terms for a ₹69.7 crore share buyback following a board meeting on August 8, 2026.
Why it mattersThe buyback utilizes the company's liquid surplus (₹546 crore as per latest context) to return capital to shareholders, which can improve Earnings Per Share (EPS) and Return on Equity (ROE) by reducing the total share count.
Maximum Buyback Price: ₹500Maximum Buyback Size: ₹69.7 CrBuyback Size vs Standalone Net Worth: 9.99%Minimum Utilization Amount: ₹52.275 CrIndicative Max Shares to Buy: 1,394,000Buyback Size vs Market Cap: ~0.65%
📅 Short termThe announcement is likely to provide price support as the company begins purchasing shares from the open market, especially given the high maximum price ceiling.
📈 Long termThe reduction in equity base is structurally positive for return ratios, though the small size relative to market cap (0.65%) makes the overall impact modest.
⚠ Risk flags
- Open market buybacks do not guarantee the maximum price to shareholders
- Actual number of shares bought depends on market price volatility during the offer period
Key Highlights
Maximum buyback size of ₹69.7 crore, capped at 9.99% of standalone net worth.
Maximum buyback price of ₹500 per share, a 58.7% premium over the closing price of ₹314.95 on August 1, 2026.
Minimum utilization requirement of 75% of the buyback size, totaling ₹52.275 crore.
Indicative maximum of 1,394,000 shares to be bought back, representing 1.24% of total paid-up equity.
The buyback will be conducted via the open market route on BSE and NSE over a period of up to 66 working days.
👀 What to Watch
Investors should monitor the daily buyback disclosures to track the actual volume and average price of shares purchased by the company. Note that in an open market buyback, the company is not obligated to buy at the maximum price of ₹500.
₹69.7 Cr Buyback Approved at Max ₹500/share via Open Market
Advanced Enzyme Technologies has formally approved a buyback of equity shares for an aggregate amount not exceeding ₹69.7 crore. The maximum buyback price is set at ₹500 per share, representing a significant premium of approximately 67% over the current market price of ₹298.3. The buyback will be conducted via the open market route, excluding promoters, and represents 9.99% of the company's standalone net worth. The company is legally obligated to utilize at least 75% of the maximum buyback size, amounting to ₹52.275 crore.
Confidence: HIGH
What changedThe company has moved from a proposal to a formal board resolution to return ₹69.7 crore to shareholders through open market share purchases.
Why it mattersThe buyback utilizes approximately 12.7% of the company's liquid surplus to reduce equity base and potentially improve EPS and ROE, while signaling management's confidence in the stock's value.
Maximum Buyback Size: ₹69.7 crMaximum Buyback Price: ₹500Buyback vs Net Worth: 9.8%Buyback vs Market Cap: 0.65%Minimum Utilization: ₹52.275 cr
📅 Short termThe high maximum price cap of ₹500 is likely to provide positive sentiment and potential price support in the immediate weeks as the company begins purchasing shares from the market.
📈 Long termThe long-term impact is limited due to the relatively small size of the buyback (1.24% of equity), but it confirms a disciplined capital allocation strategy regarding idle cash.
⚠ Risk flags
- Open market route does not guarantee the maximum price will be reached
- Small size relative to total market capitalization
Key Highlights
Maximum buyback size of ₹69.7 crore, representing 9.99% of standalone paid-up capital and free reserves.
Maximum buyback price of ₹500 per share, a 58.7% premium over the closing price prior to the board meeting intimation.
Indicative maximum of 1,394,000 shares to be bought back, which is 1.24% of the total paid-up equity.
Minimum utilization requirement of 75% of the buyback size, totaling ₹52.275 crore.
Buyback to be funded entirely through internal accruals and liquid surplus, which was ₹546 crore as per recent filings.
👀 What to Watch
Investors should monitor daily exchange disclosures to track the actual volume and price of shares bought back by the company. Note that in an open market buyback, the company is not obligated to buy at the maximum price of ₹500, but rather at prevailing market rates up to that limit.
Rs 69.7 Cr Buyback Announced at Max Price of Rs 500 per Share
Advanced Enzyme Technologies has announced a share buyback from the open market for a maximum value of Rs 69.7 crore. The maximum buyback price is set at Rs 500 per share, representing a significant premium over the current market price of Rs 298.3. The company intends to utilize at least 75% of the maximum size (Rs 52.275 crore) for this purpose. The buyback is scheduled to open on August 14, 2026, and will conclude by November 20, 2026, or earlier if the maximum size is reached.
Confidence: HIGH
What changedThe company has transitioned from a board-approved proposal to a formal public announcement for a share repurchase program via the open market.
Why it mattersThe buyback utilizes a portion of the company's Rs 546 crore liquid surplus to reduce the share count, which is expected to improve Earnings Per Share (EPS) and Return on Equity (ROE) for remaining shareholders.
Maximum Buyback Size: Rs 69.7 crMaximum Buyback Price: Rs 500Buyback vs Market Cap: 0.65%Buyback vs Consolidated Net Worth: 5.09%Minimum Buyback Size: Rs 52.275 cr
📅 Short termThe announcement is likely to be viewed positively by the market, potentially providing a floor for the stock price as the company begins purchasing shares from the open market starting August 14.
📈 Long termWhile the buyback size is relatively small (1.25% of capital), it demonstrates management's commitment to capital allocation and confidence in the business's intrinsic value.
⚠ Risk flags
- Open market buybacks do not guarantee the full maximum amount will be spent
- Actual purchase price may be significantly lower than the Rs 500 maximum cap
Key Highlights
Maximum buyback size of Rs 69.7 crore, representing 5.09% of consolidated net worth.
Maximum buyback price of Rs 500 per share, a ~67% premium to the current price of Rs 298.3.
Minimum buyback size commitment of Rs 52.275 crore (75% of maximum size).
Indicative maximum of 1,394,000 shares to be repurchased, approximately 1.25% of total paid-up capital.
Buyback period starts on August 14, 2026, and ends by November 20, 2026.
👀 What to Watch
Investors should monitor the daily buyback volumes and prices on the NSE/BSE starting August 14. As this is an open market buyback, the company will purchase shares at prevailing market prices up to the Rs 500 limit, which may provide short-term price support.
Q1 FY27 PAT down 5% to ₹38.6 Cr; Specialized Manufacturing grows 41% YoY
Advanced Enzyme Technologies reported a weak Q1 FY27 with consolidated PAT declining 5% YoY to ₹38.6 Cr and 15% sequentially. While revenue grew marginally by 2% YoY to ₹189.8 Cr, EBITDA margins contracted significantly to 27% from 30% in the previous year. The core Human Nutrition segment (60% of revenue) saw a 7% YoY decline, which was partially offset by strong growth in Specialized Manufacturing (+41%) and Industrial Bio-processing (+30%). Geographically, growth in Asia (+37%) was countered by a 4% decline in the domestic Indian market.
Confidence: HIGH
What changedThe company experienced a margin squeeze in Q1 FY27, with EBITDA falling 10% despite a slight revenue increase, alongside a slowdown in its largest business segment (Human Nutrition).
Why it mattersThe margin contraction to 27% is a deviation from the company's target of 33-35%, signaling potential pricing pressure or higher input costs. The growth in specialized segments is positive but currently too small to fully offset core segment weakness.
Q1 FY27 Revenue: ₹189.8 CrQ1 FY27 PAT: ₹38.6 CrEBITDA Margin: 27%Human Nutrition Revenue Share: 60%Specialized Manufacturing Growth (YoY): 41%Liquid Surplus: ₹54.6 Cr
📅 Short termThe stock may face downward pressure in the short term due to the 15% sequential decline in PAT and the contraction in operating margins.
📈 Long termLong-term prospects depend on the successful scale-up of the Specialized Manufacturing and Bio-catalysis segments, and the company's ability to leverage its R&D to maintain a 15% revenue CAGR.
⚠ Risk flags
- Margin compression
- High revenue concentration in Human Nutrition (60%)
- Regulatory risks in the US market (29% of revenue)
Key Highlights
Consolidated revenue grew 2% YoY to ₹189.8 Cr, but declined 7% on a sequential basis.
EBITDA de-grew by 10% YoY to ₹51.0 Cr, with margins contracting to 27% from 30% in Q1 FY26.
Specialized Manufacturing segment outperformed with 41% YoY growth, reaching ₹20.0 Cr.
Human Nutrition segment revenue fell 7% YoY to ₹113.9 Cr, contributing 60% of total sales.
Liquid surplus of ₹54.6 Cr maintained for potential inorganic acquisitions and R&D investment.
👀 What to Watch
Investors should monitor the recovery of the Human Nutrition segment and the company's ability to restore EBITDA margins toward its historical 30-35% range. The execution of the 'Bio-catalysis' opportunity for API manufacturers is a key growth driver to watch in upcoming quarters.
Q1 FY27 Results: PAT down 5% to ₹38.6 Cr; EBITDA margins contract to 27%
Advanced Enzyme Technologies reported a modest 2% YoY revenue growth at ₹189.8 Cr for Q1 FY27, but faced significant margin pressure. EBITDA declined 10% YoY to ₹51 Cr, with margins contracting to 27% from 30% in the year-ago period. The decline was primarily driven by a 7% drop in the core Human Nutrition segment due to lower Pharma/API sales. While Bio-Processing and Specialized Manufacturing grew 30% and 41% respectively, they were insufficient to maintain overall profitability levels, leading to a 5% YoY decline in PAT to ₹38.6 Cr.
Confidence: HIGH
What changedThe company experienced a shift in segment performance where high-growth Bio-Processing and Specialized Manufacturing were offset by a decline in the dominant Human Nutrition segment, leading to overall margin compression.
Why it mattersThe margin drop to 27% is significant as it deviates from the company's historical operational efficiency. The decline in the core Human Nutrition segment (60% of revenue) suggests competitive or demand headwinds in the Pharma/API space.
Q1 FY27 Revenue: ₹189.8 CrQ1 FY27 PAT: ₹38.6 CrEBITDA Margin: 27%Human Nutrition YoY Growth: -7%Specialized Manufacturing YoY Growth: +41%Q1 Revenue vs FY26 Revenue: 25.4%
📅 Short termThe stock may face downward pressure in the short term due to the 10% YoY decline in EBITDA and the sequential 15% drop in PAT.
📈 Long termLong-term prospects depend on the successful scale-up of the Specialized Manufacturing segment and the ability to pass on costs to restore margins to the 30%+ level.
⚠ Risk flags
- EBITDA margin contraction
- Decline in core Human Nutrition/API segment
- Negative sequential growth in domestic sales (-12% QoQ)
Key Highlights
Consolidated Revenue grew 2% YoY to ₹1,898 million, but declined 7% on a sequential (QoQ) basis.
EBITDA margins contracted to 27% in Q1 FY27, down from 31% in the previous quarter and 30% YoY.
Human Nutrition segment revenue declined 7% YoY to ₹1,139 million, impacted by lower Pharma/API sales.
Specialized Manufacturing segment grew 41% YoY to ₹200 million, now contributing 11% of total revenue.
International sales increased to 51% of total revenue mix, with Europe and Asia (ex-India) growing 44% and 37% respectively.
👀 What to Watch
Investors should monitor the stabilization of EBITDA margins, which have fallen below the company's historical 30-35% target range. Key focus areas include the recovery of the Pharma/API business and the execution of the new B2C brand 'Wellfa' in the Indian market.
₹69.7 Cr Buyback at ₹500/Share and 100% Consolidation of JC Biotech
Advanced Enzyme Technologies has approved a buyback of up to 13.94 lakh shares at a maximum price of ₹500 per share, representing a 54% premium to the current market price. The buyback size of ₹69.7 crore accounts for 5.09% of the consolidated net worth. Additionally, the company will acquire the remaining 4.28% stake in JC Biotech to make it a wholly-owned subsidiary and infuse ₹2 crore into Advanced Nutrazyme. These moves utilize the company's significant liquid surplus of ₹546 crore to simplify corporate structure and reward shareholders.
Confidence: HIGH
What changedThe company has initiated a capital return program via a buyback and moved to fully consolidate its subsidiary JC Biotech by acquiring the minority stake.
Why it mattersThe high buyback price (₹500 vs ₹324 market price) signals management's view that the stock is undervalued. Full ownership of JC Biotech simplifies the corporate structure and allows for total control over its cash flows and operations.
Maximum Buyback Price: ₹500Maximum Buyback Size: ₹69.7 CrBuyback vs Consolidated Net Worth: 5.09%Stake to be acquired in JC Biotech: 4.28%Fund infusion in Advanced Nutrazyme: ₹2 Cr
📅 Short termThe high premium on the buyback price is likely to provide a positive sentiment boost to the stock price in the coming weeks.
📈 Long termThe consolidation of subsidiaries and efficient use of cash reserves support the company's strategy of maintaining high ROCE (24%) and simplifying its business model.
⚠ Risk flags
- Open market buybacks do not guarantee the full amount will be utilized if market prices exceed the cap
- Minority stake acquisition is small and unlikely to change consolidated earnings significantly
Key Highlights
Approved buyback of up to 1,394,000 equity shares at a maximum price of ₹500 per share via open market route
Maximum buyback size of ₹69.7 crore represents 9.99% of standalone and 5.09% of consolidated net worth
Acquisition of the remaining 4.28% stake in JC Biotech Private Limited to make it a 100% subsidiary
Additional fund infusion of up to ₹20 million (₹2 crore) in Advanced Nutrazyme Private Limited
Buyback price of ₹500 is a significant premium over the current market price of ₹324.4
👀 What to Watch
Investors should monitor the public announcement for the buyback start date and observe the impact of 100% ownership of JC Biotech on future consolidated margins.
₹69.7 Cr Buyback at max ₹500/share; 100% consolidation of JC Biotech approved
Advanced Enzyme Technologies has approved a buyback of up to ₹69.7 crore via the open market route at a maximum price of ₹500 per share, a ~54% premium to the current price. The board also cleared the acquisition of the remaining 4.28% stake in JC Biotech Private Limited, making it a wholly-owned subsidiary. Additionally, a small capital infusion of ₹2 crore was approved for Advanced Nutrazyme. These moves utilize the company's strong cash position to consolidate holdings and return capital to shareholders.
Confidence: HIGH
What changedThe company has initiated a capital return program via an open market buyback and moved to fully consolidate its ownership in JC Biotech.
Why it mattersThe buyback at a high premium signals management's confidence in the company's valuation, while the subsidiary consolidation simplifies the corporate structure and eliminates minority interest leakage.
Maximum Buyback Size: ₹69.7 crMaximum Buyback Price: ₹500 per shareBuyback vs Net Worth: ~9.8%Stake to be acquired in JCB: 4.28%Infusion in ANPL: ₹2 cr
📅 Short termThe high buyback price premium is likely to support the stock price in the near term, providing a floor during the open market purchase period.
📈 Long termConsolidating subsidiaries and utilizing surplus cash for buybacks improves capital efficiency, though the long-term trajectory depends on the 15% revenue growth target and US market penetration.
⚠ Risk flags
- Open market buybacks do not guarantee the full amount will be spent or the maximum price will be reached
- Small buyback size relative to total market cap (0.6%)
Key Highlights
Maximum buyback size of ₹69.7 crore represents 9.99% of standalone paid-up capital and free reserves.
Maximum buyback price set at ₹500 per share, significantly above the current market price of ₹324.4.
Acquisition of the remaining 4.28% equity in JC Biotech Private Limited to achieve 100% ownership.
Approved infusion of up to ₹20 million (₹2 crore) into wholly-owned subsidiary Advanced Nutrazyme Private Limited.
Indicative maximum buyback of 1,394,000 equity shares, representing 1.24% of total paid-up capital.
👀 What to Watch
Investors should monitor the public announcement for the buyback start date and review the Q1 FY27 financial results for margin stability, as the company targets a 15% CAGR.
₹69.7 Cr Buyback at ₹500/share; 100% Consolidation of JC Biotech Approved
Advanced Enzyme Technologies has approved a buyback of equity shares worth up to ₹69.7 crore via the open market route at a maximum price of ₹500 per share. This maximum price represents a significant 54% premium over the current market price of ₹324.4. The board also approved acquiring the remaining 4.28% stake in JC Biotech to make it a wholly-owned subsidiary and a ₹2 crore fund infusion into Advanced Nutrazyme. These moves indicate a focus on consolidating subsidiary holdings and returning capital to shareholders using its liquid surplus.
Confidence: HIGH
What changedThe company has initiated a share buyback program and moved to fully consolidate its 95.72% subsidiary, JC Biotech, into a wholly-owned entity.
Why it mattersThe buyback at a high price ceiling suggests management believes the stock is undervalued, while the subsidiary consolidation simplifies the corporate structure and eliminates minority interest leakage.
Maximum Buyback Size: ₹69.7 crMaximum Buyback Price: ₹500 per shareBuyback vs Market Cap: 0.60%JCB Stake Acquisition: 4.28%ANPL Fund Infusion: ₹2 cr
📅 Short termThe stock is likely to react positively to the buyback announcement, especially given the high maximum price of ₹500 compared to the current market price.
📈 Long termFull ownership of JC Biotech and continued investment in Nutrazyme align with the company's strategy to expand its specialized manufacturing and human nutrition segments.
⚠ Risk flags
- Open market buybacks do not guarantee the full deployment of the maximum buyback size
- Execution risk in the specialized manufacturing segment expansion
Key Highlights
Maximum buyback size of ₹69.7 crore, representing 9.99% of standalone paid-up equity capital and free reserves.
Maximum buyback price set at ₹500 per share, a ~54% premium to the current market price of ₹324.4.
Acquisition of the remaining 4.28% stake in JC Biotech Private Limited to make it a 100% subsidiary.
Approved infusion of up to ₹20 million (₹2 crore) in wholly-owned subsidiary Advanced Nutrazyme Private Limited.
Indicative maximum number of shares to be bought back is 1,394,000, representing 1.24% of existing paid-up capital.
👀 What to Watch
Investors should watch for the Public Announcement regarding the buyback timeline and the specific Q1 FY27 earnings performance to assess if operational margins (historically ~30%) are being maintained.
₹1.35 Dividend: Advanced Enzyme Sets July 24 as Record Date for FY26 Final Payout
Advanced Enzyme Technologies has fixed July 24, 2026, as the record date to determine shareholder eligibility for a final dividend of ₹1.35 per equity share (face value ₹2) for FY26. The dividend is subject to approval at the 37th Annual General Meeting (AGM) scheduled for July 31, 2026. If approved, the payout will be made on or after August 03, 2026. Based on the current market price of ₹324, this represents a modest dividend yield of approximately 0.42%.
Confidence: HIGH
What changedThe company has finalized the administrative timeline (Record Date and AGM Date) for the dividend payout previously recommended by the Board in May 2026.
Why it mattersThis is a routine corporate action confirming the distribution of profits to shareholders. While the yield is low at 0.42%, it reflects the company's consistent dividend-paying track record alongside its high ROCE of 24%.
Dividend per share: ₹1.35Record Date: July 24, 2026Dividend Yield: ~0.42%TTM EPS: ₹15.08Dividend Payout Ratio: ~9%
📅 Short termThe stock price may see a minor adjustment on the ex-dividend date (around July 23-24) reflecting the payout amount.
📈 Long termLimited. This is a routine annual event and does not alter the company's structural growth profile or its focus on specialized manufacturing and US market expansion.
Key Highlights
Final dividend of ₹1.35 per equity share recommended for the financial year 2025-26.
Record date for dividend entitlement fixed as July 24, 2026.
37th Annual General Meeting (AGM) to be held on July 31, 2026, via video conferencing.
Dividend payment date scheduled for on or after August 03, 2026, post-shareholder approval.
Dividend payout represents approximately 9% of the TTM EPS of ₹15.08.
👀 What to Watch
Investors interested in the dividend must hold the shares in their demat account before the ex-dividend date (typically one working day prior to the July 24 record date). Monitor the AGM on July 31 for management updates on the 15% CAGR revenue growth strategy.
Advanced Enzyme Reports Record FY26 Revenue of ₹7,458 Million, PAT Up 30% YoY
Advanced Enzyme Technologies achieved its highest-ever quarterly and annual revenue in FY26, with annual turnover reaching ₹7,458 million, a 17% increase. The company's net profit for the year grew by 30% to ₹1,736 million, supported by a strong and consistent EBITDA margin of 31%. Growth was broad-based across segments, with Human Healthcare contributing 63% of revenue and Animal Healthcare growing by 25% YTD. Management remains optimistic about future growth driven by new R&D capabilities and regulatory filings in the US and Europe.
Key Highlights
Reported highest-ever annual revenue of ₹7,458 million, representing 17% YoY growth.
Q4 FY26 PAT surged 69% YoY to ₹453 million with a PAT margin of 22%.
EBITDA margins remained robust and consistent at 31% for both the quarter and the full year.
Animal Healthcare segment showed strong momentum with 25% YTD growth, while Human Healthcare grew 15%.
Subsidiary Evoxx turned profitable with a 50% revenue increase to ₹319 million in FY26.
👀 What to Watch
Investors should maintain a positive outlook given the record-breaking performance and consistent 31% EBITDA margins. Key catalysts to monitor include the operationalization of the Nashik R&D center and pending European approvals for anti-inflammatory products.
Advanced Enzyme Q4 FY26: PAT Surges 69% YoY to ₹453 Million; EBITDA Margins Expand to 31%
Advanced Enzyme Technologies reported a strong set of numbers for Q4 FY26, with consolidated revenue growing 22% YoY to ₹2,034 million. The bottom line saw significant outperformance as PAT jumped 69% YoY to ₹453 million, driven by improved operational efficiencies and a 51% surge in domestic sales. EBITDA margins expanded by 400 basis points YoY to reach 31%. For the full year FY26, the company recorded a 30% growth in PAT, reaching ₹1,736 million, while maintaining its status as a zero-debt entity.
Key Highlights
Q4 FY26 Revenue grew 22% YoY to ₹2,034 million, while full-year FY26 revenue rose 17% to ₹7,458 million.
Quarterly PAT increased 69% YoY to ₹453 million, with EPS rising to ₹3.84 from ₹2.37.
EBITDA margins improved to 31% in Q4 FY26 from 27% in Q4 FY25, reflecting strong pricing power and cost management.
Domestic sales grew 51% YoY, now accounting for 52% of total revenue compared to 42% in the previous year.
Human Nutrition segment, the company's largest, grew 24% YoY to ₹1,281 million driven by Pharma and Bio-catalysis.
👀 What to Watch
Investors should take note of the significant margin expansion and the robust 51% growth in the domestic market. The company's transition towards B2C through the 'Wellfa' brand and its zero-debt balance sheet make it a strong candidate for long-term portfolios in the specialty biotech space.
Advanced Enzyme Q4 FY26 PAT Surges 69% YoY to ₹453 Million; Revenue Up 22%
Advanced Enzyme Technologies delivered a robust performance in Q4 FY26, with consolidated revenue growing 22% YoY to ₹2,034 million. Profitability saw a significant jump as PAT surged 69% YoY to ₹453 million, driven by a 39% increase in EBITDA. For the full year FY26, the company reported a 17% growth in revenue and a 30% increase in PAT, with EPS rising to ₹15.08. While the Indian and Asian markets showed strong double-digit growth, the Americas market faced a 7% decline during the fiscal year.
Key Highlights
Q4 FY26 PAT increased 69% YoY to ₹453 million with PAT margins improving to 22%.
EBITDA grew 39% YoY to ₹632 million in Q4 FY26, maintaining a healthy margin of 31%.
Human Nutrition segment, the largest contributor (63% of revenue), grew 24% YoY in Q4.
India revenue grew 28% YoY in FY26, while Asia (ex-India) surged by 53%.
Maintained a strong balance sheet with a Net Debt to Equity ratio of 0.01 and ROE improving to 11.37%.
👀 What to Watch
Investors should view the strong margin expansion and domestic growth positively, though the slight decline in the Americas market warrants monitoring. The stock remains a solid play on the specialized enzyme and biotech sector given its debt-free status and consistent profitability.
Advanced Enzyme FY26: ₹1.35 Final Dividend Recommended; 49,350 ESOP Shares Allotted
Advanced Enzyme Technologies has recommended a final dividend of ₹1.35 per share for FY26 while deferring an interim dividend to preserve capital for strategic growth opportunities. The company also announced the allotment of 49,350 equity shares under its 2022 ESOP scheme, marginally increasing the total paid-up capital. Leadership stability is maintained with the re-appointment of the Whole Time Director for another five years and the addition of a new Independent Director. The board's decision to retain cash suggests a focus on potential M&A or expansion activities in the near future.
Key Highlights
Recommended a final dividend of ₹1.35 per share (67.5% of face value) for FY 2025-26.
Allotted 49,350 equity shares following ESOP exercises, increasing total shares to 11,19,76,150.
Deferred interim dividend to preserve liquidity for potential strategic corporate actions.
Re-appointed Mr. Mukund Madhusudan Kabra as Whole Time Director for a 5-year term starting April 2027.
Appointed Mr. Pradip Bhailal Shah as an Independent Director for a 5-year term effective June 2026.
👀 What to Watch
Investors should view the capital preservation as a signal for future expansion or acquisitions and hold for long-term value. Monitor the upcoming AGM for final dividend confirmation and updates on strategic plans.
Advanced Enzyme Recommends ₹1.35 Dividend and Re-appoints Statutory Auditors
Advanced Enzyme Technologies has recommended a final dividend of ₹1.35 per share for FY26, representing 67.5% of the face value. The board has decided to defer an interim dividend to preserve capital for potential strategic acquisitions or corporate actions, signaling a focus on long-term growth. MSKA & Associates LLP has been re-appointed as statutory auditors for a second five-year term following an unmodified audit report. Furthermore, the company strengthened its leadership with the re-appointment of Mukund Kabra as Whole Time Director and the addition of Pradip Bhailal Shah as an Independent Director.
Key Highlights
Recommended a final dividend of ₹1.35 per share (67.5% of face value) for FY 2025-26.
Re-appointed MSKA & Associates LLP as Statutory Auditors for a 5-year term until 2031.
Allotted 49,350 equity shares under ESOP 2022, increasing paid-up capital to ₹22.39 crore.
Deferred interim dividend to maintain liquidity for potential strategic growth opportunities.
Re-appointed Mukund Madhusudan Kabra as Whole Time Director for another 5-year term starting April 2027.
👀 What to Watch
Investors should monitor the company's use of preserved capital, as the deferral of the interim dividend suggests potential M&A or expansion activity. The continuity in management and auditing provides a stable outlook for long-term shareholders.
Advanced Enzyme Recommends ₹1.35 Dividend; Appoints Pradip Shah as Independent Director
Advanced Enzyme Technologies has recommended a final dividend of ₹1.35 per share (67.5%) for FY 2025-26. The Board has strategically deferred an interim dividend to preserve cash for potential acquisitions and corporate actions aimed at long-term value. Key leadership changes include the appointment of Mr. Pradip Bhailal Shah as an Independent Director and the re-appointment of Mr. Mukund Kabra as Whole Time Director. The company also expanded its share capital by allotting 49,350 shares through its ESOP program.
Key Highlights
Final dividend of ₹1.35 per share recommended, subject to shareholder approval at the 37th AGM.
Mr. Pradip Bhailal Shah appointed as Independent Director for a 5-year term starting June 12, 2026.
Capital preservation strategy initiated to evaluate potential strategic M&A opportunities instead of interim dividend.
Allotment of 49,350 equity shares under the ESOP 2022 scheme, increasing paid-up capital to ₹22.39 crore.
Re-appointment of MSKA & Associates LLP as Statutory Auditors for a second 5-year term.
👀 What to Watch
Investors should monitor for potential M&A announcements as the company is explicitly hoarding cash for strategic growth. The dividend recommendation and management stability are positive indicators for long-term holders.
Advanced Enzyme Recommends ₹1.35 Final Dividend and Re-appoints Executive Director
Advanced Enzyme Technologies has recommended a final dividend of ₹1.35 per share (67.5% of face value) for FY 2025-26, pending shareholder approval. The Board has decided to defer an interim dividend to preserve capital for potential strategic acquisitions and corporate actions aimed at long-term value. Key leadership continuity is ensured with the re-appointment of Mr. Mukund Madhusudan Kabra as Whole Time Director for a five-year term starting April 2027. Additionally, the company expanded its equity base by allotting 49,350 shares under its ESOP scheme.
Key Highlights
Recommended a final dividend of ₹1.35 per equity share on a face value of ₹2 each.
Re-appointed Mr. Mukund Madhusudan Kabra as Whole Time Director for a 5-year term from 2027 to 2032.
Allotted 49,350 equity shares under ESOP 2022, increasing paid-up capital to ₹22.39 crore.
Deferred interim dividend to maintain liquidity for potential strategic growth and corporate actions.
Appointed Mr. Pradip Bhailal Shah as an Additional Independent Director for a 5-year term.
👀 What to Watch
Investors should view the dividend and management continuity as signs of stability, while the decision to preserve capital suggests upcoming strategic investments or M&A activity. Monitor the upcoming AGM for final dividend approval and further clarity on the 'strategic avenues' mentioned by the board.
Advanced Enzyme Recommends ₹1.35 Final Dividend, Defers Interim Payout for Strategic Flexibility
Advanced Enzyme Technologies has recommended a final dividend of ₹1.35 per share (67.5%) for FY 2025-26, pending shareholder approval. Notably, the Board has decided to defer the declaration of an interim dividend to preserve capital for potential strategic avenues and corporate actions aimed at maximizing long-term shareholder value. The company also announced the re-appointment of Mr. Mukund Kabra as Whole Time Director and the appointment of a new Independent Director. Additionally, 49,350 shares were allotted under the ESOP scheme, slightly increasing the paid-up capital.
Key Highlights
Recommended a final dividend of ₹1.35 per equity share (67.5% of face value ₹2) for FY 2025-26.
Interim dividend deferred to maintain liquidity and flexibility for potential strategic acquisitions or corporate actions.
Re-appointed Mr. Mukund Madhusudan Kabra as Whole Time Director for a 5-year term effective April 2027.
Allotted 49,350 equity shares under ESOP 2022, increasing total paid-up share capital to ₹22.39 crore.
Appointed Mr. Pradip Bhailal Shah as an Additional Director (Independent) for a 5-year term.
👀 What to Watch
Investors should monitor the company for potential M&A or expansion announcements, as the decision to preserve capital suggests a strategic move is being evaluated. The steady final dividend provides some yield, but the growth narrative will depend on how the preserved capital is deployed.
Advanced Enzyme Recommends ₹1.35 Final Dividend; Defers Interim Dividend for Strategic Growth
Advanced Enzyme Technologies has recommended a final dividend of ₹1.35 per equity share (67.5% of face value) for FY 2025-26. Notably, the Board decided to defer the declaration of an interim dividend to preserve capital for potential strategic acquisitions and corporate actions, despite maintaining a healthy liquidity position. The company also announced the re-appointment of Mukund Kabra as Whole Time Director for five years and the appointment of Pradip Bhailal Shah as an Independent Director. Additionally, 49,350 shares were allotted under the ESOP 2022 scheme, marginally increasing the paid-up capital.
Key Highlights
Recommended a final dividend of ₹1.35 per equity share (67.5% of ₹2 face value) for FY26.
Board deferred interim dividend declaration to preserve capital for future strategic avenues.
Re-appointed Mukund Madhusudan Kabra as Whole Time Director for a 5-year term starting April 2027.
Allotted 49,350 equity shares under ESOP 2022, increasing paid-up capital to ₹22.39 crore.
Re-appointed MSKA & Associates LLP as Statutory Auditors for a second 5-year term.
👀 What to Watch
Investors should focus on the management's commentary regarding 'strategic avenues,' which hints at potential M&A activity. While the dividend is a positive yield event, the capital preservation strategy suggests a shift toward growth-oriented investments.
Advanced Enzyme Recommends ₹1.35 Dividend; Defers Interim Payout for Strategic Flexibility
Advanced Enzyme Technologies has recommended a final dividend of ₹1.35 per share for FY26, representing a 67.5% payout on face value. The Board has strategically decided to defer an interim dividend to preserve capital for potential future acquisitions or corporate actions. Management continuity is ensured with the re-appointment of Whole Time Director Mukund Kabra for another five-year term. The company also expanded its equity base slightly by allotting 49,350 shares through its ESOP scheme.
Key Highlights
Recommended final dividend of ₹1.35 per equity share (67.5% of face value) for FY 2025-26.
Deferred interim dividend to preserve capital for potential strategic avenues and corporate actions.
Re-appointed Mr. Mukund Madhusudan Kabra as Whole Time Director for a 5-year term (2027-2032).
Allotted 49,350 equity shares under ESOP 2022, increasing paid-up capital to ₹22.40 crore.
Appointed Mr. Pradip Bhailal Shah as an Independent Director for a 5-year term starting June 2026.
👀 What to Watch
Investors should monitor the company's 'strategic avenues' as the decision to preserve capital suggests potential M&A activity. The management continuity and consistent dividend policy support a long-term hold strategy.
